Adams, H.C. 3rd, Stevenaert, F., Krejcik, J., Van der Borght, K., Smets, T., Bald, J., Abraham, Y., Ceulemans, H., Chiu, C., Vanhoof, G., Usmani, S.Z., Plesner, T., Lonial, S., Nijhof, I., Lokhorst, H.M., Mutis, T., van de Donk, N.W.C.J., Sasser, A.K. & Casneuf, T. (2019) High-parameter mass cytometry evaluation of relapsed/refractory multiple myeloma patients treated with daratumumab demonstrates immune modulation as a novel mechanism of action. Cytometry. Part A: The Journal of the International Society for Analytical Cytology, 95, 279–289.
Ansell, S.M., Lesokhin, A.M., Borrello, I., Halwani, A., Scott, E.C., Gutierrez, M., Schuster, S.J., Millenson, M.M., Cattry, D., Freeman, G.J., Rodig, S.J., Chapuy, B., Ligon, A.H., Zhu, L., Grosso, J.F., Kim, S.Y., Timmerman, J.M., Shipp, M.A. & Armand, P. (2015) PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. The New England Journal of Medicine, 372, 311–319.
Bailur, J.K., McCachren, S.S., Doxie, D.B., Shrestha, M., Pendleton, K., Nooka, A.K., Neparidze, N., Parker, T.L., Bar, N., Kaufman, J.L., Hofmeister, C.C., Boise, L.H., Lonial, S., Kemp, M.L., Dhodapkar, K.M. & Dhodapkar, M.V. (2019) Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy. JCI Insight, 5, pii:127807.
Dispenzieri, A. & Buadi, F.K. (2013) A review of POEMS syndrome. Oncology (Williston Park, N.Y.), 27, 1242–1250.
Galli, E., Friebel, E., Ingelfinger, F., Unger, S., Nunez, N.G. & Becher, B. (2019) The end of omics? High dimensional single cell analysis in precision medicine. European Journal of Immunology, 49, 212–220.
De Goycoechea, D., Stalder, G., Martins, F. & Duchosal, M.A. (2019) Immune checkpoint inhibition in classical Hodgkin lymphoma: from early achievements towards new perspectives. Journal of Oncology, 2019, 9513701.
Keddie, S. & Lunn, M.P. (2018) POEMS syndrome. Current Opinion in Neurology, 31, 551–558.
Kourelis, T.V., Villasboas, J.C., Jessen, E., Dasari, S., Dispenzieri, A., Jevremovic, D. & Kumar, S. (2019) Mass cytometry dissects T cell heterogeneity in the immune tumor microenvironment of common dysproteinemias at diagnosis and after first line therapies. Blood Cancer Journal, 9, 72.
Marsh-wakefield, F., Kruzins, A., Mcguire, H.M., Yang, S., Gibson, J., Brown, C., Larsen, S. & Mcculloch, D. (2019) Mass cytometry discovers two discrete subsets of CD39− Treg which discriminate MGUS from multiple myeloma. Frontiers in Immunology, 10, 1–12.
Neri, P., Maity, R., Tagoug, I., McCulloch, S., Duggan, P., Jimenez-Zepeda, V., Tay, J., Thakurta, A. & Bahlis, N. (2018) Immunome single cell profiling reveals T cell exhaustion with upregulation of checkpoint inhibitors LAG3 and tigit on marrow infiltrating T lymphocytes in daratumumab and IMiDs resistant patients. Blood, 132, 242.
